JP2016523250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523250A5 JP2016523250A5 JP2016521489A JP2016521489A JP2016523250A5 JP 2016523250 A5 JP2016523250 A5 JP 2016523250A5 JP 2016521489 A JP2016521489 A JP 2016521489A JP 2016521489 A JP2016521489 A JP 2016521489A JP 2016523250 A5 JP2016523250 A5 JP 2016523250A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- pharmaceutical dosage
- beads
- cysteamine
- motomeko
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011324 bead Substances 0.000 claims description 98
- 239000002552 dosage form Substances 0.000 claims description 94
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 52
- 229960003151 mercaptamine Drugs 0.000 claims description 52
- 239000007771 core particle Substances 0.000 claims description 32
- 238000009826 distribution Methods 0.000 claims description 29
- 239000002245 particle Substances 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 8
- 238000004007 reversed phase HPLC Methods 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- 238000000825 ultraviolet detection Methods 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 6
- 229940099500 cystamine Drugs 0.000 claims description 6
- 239000007902 hard capsule Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- NSKJTUFFDRENDM-ZVGUSBNCSA-N 2-aminoethanethiol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound NCCS.OC(=O)[C@H](O)[C@@H](O)C(O)=O NSKJTUFFDRENDM-ZVGUSBNCSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 229940008046 cysteamine bitartrate Drugs 0.000 claims description 4
- 238000001125 extrusion Methods 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 238000005563 spheronization Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000002702 enteric coating Substances 0.000 claims description 2
- 238000009505 enteric coating Methods 0.000 claims description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 150000003892 tartrate salts Chemical class 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361835965P | 2013-06-17 | 2013-06-17 | |
| US61/835,965 | 2013-06-17 | ||
| PCT/US2014/042607 WO2014204881A1 (en) | 2013-06-17 | 2014-06-17 | Delayed release cysteamine bead formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523250A JP2016523250A (ja) | 2016-08-08 |
| JP2016523250A5 true JP2016523250A5 (enExample) | 2017-08-03 |
| JP6468661B2 JP6468661B2 (ja) | 2019-02-13 |
Family
ID=52019418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521489A Active JP6468661B2 (ja) | 2013-06-17 | 2014-06-17 | 遅延放出システアミンビーズ処方、ならびにその作製方法および使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US9233077B2 (enExample) |
| EP (2) | EP3010491A4 (enExample) |
| JP (1) | JP6468661B2 (enExample) |
| KR (2) | KR102281747B1 (enExample) |
| CN (2) | CN105492000B (enExample) |
| AP (1) | AP2015008925A0 (enExample) |
| AR (2) | AR096628A1 (enExample) |
| AU (1) | AU2014281702C1 (enExample) |
| BR (1) | BR112015031417B1 (enExample) |
| CA (2) | CA2938644C (enExample) |
| CL (1) | CL2015003662A1 (enExample) |
| CU (1) | CU20150178A7 (enExample) |
| EA (1) | EA031255B8 (enExample) |
| HK (1) | HK1218066A1 (enExample) |
| IL (2) | IL302141A (enExample) |
| MX (1) | MX375377B (enExample) |
| NI (1) | NI201500177A (enExample) |
| NZ (1) | NZ714517A (enExample) |
| PH (2) | PH12020552266A1 (enExample) |
| SG (1) | SG11201510126QA (enExample) |
| TN (1) | TN2015000549A1 (enExample) |
| TW (1) | TWI649100B (enExample) |
| UA (1) | UA117833C2 (enExample) |
| WO (1) | WO2014204881A1 (enExample) |
| ZA (1) | ZA201508783B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI659209B (zh) * | 2013-06-17 | 2019-05-11 | 地平線罕見醫學製藥有限責任公司 | 分析半胱胺組合物的方法 |
| AR096628A1 (es) | 2013-06-17 | 2016-01-20 | Raptor Pharmaceuticals Inc | Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella |
| WO2017087532A1 (en) * | 2015-11-16 | 2017-05-26 | The Regents Of The University Of California | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds |
| US10143665B2 (en) | 2015-11-17 | 2018-12-04 | Horizon Orphan Llc | Methods for storing cysteamine formulations and related methods of treatment |
| ITUA20161799A1 (it) * | 2016-03-18 | 2017-09-18 | Recordati Ind Chimica E Farmaceutica S P A | Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale |
| EP3308773A1 (en) * | 2016-10-11 | 2018-04-18 | Recordati Industria Chimica E Farmaceutica SPA | Formulations of cysteamine and cysteamine derivatives |
| WO2018093364A1 (en) * | 2016-11-16 | 2018-05-24 | The Regents Of The University Of California | Formulations of cysteamine and cystamine |
| US10251850B2 (en) | 2017-01-11 | 2019-04-09 | Lupin Limited | Process for preparation of cysteamine bitartrate |
| AU2018236349B2 (en) * | 2017-03-15 | 2021-03-11 | Cerecin Inc. | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto |
| US20250367120A1 (en) * | 2022-06-24 | 2025-12-04 | Sunsho Pharmaceutical Co., Ltd. | Pharmaceutical composition and method for producing same |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| US4110441A (en) | 1974-04-29 | 1978-08-29 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Gamma-l-glutamyl cholamine phosphate |
| FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US4959306A (en) | 1986-11-28 | 1990-09-25 | Sclavo, Inc. | Labeling design for a binding assay reagent |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| US5639743A (en) | 1992-11-13 | 1997-06-17 | University Of Georgia Research Foundation | Compositions and methods for treating exocrine gland atrophy |
| CA2236344A1 (en) | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
| UA69413C2 (uk) * | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
| US6794414B1 (en) | 1998-06-17 | 2004-09-21 | Yeda Research And Development Co. Ltd. | Method and compositions for treating diseases mediated by transglutaminase activity |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US20050004075A1 (en) | 2000-12-13 | 2005-01-06 | Walcom Animal Science (I.P.2) Limited | Composition for regulating animal growth, method of manufacture and use thereof |
| CN1144585C (zh) | 2000-12-13 | 2004-04-07 | 华扩达动物科学[I.P.2]有限公司 | 含有半胱胺或其盐类的促进动物快速生长的组合物及用途 |
| GB2377874B (en) | 2001-07-23 | 2005-06-22 | Walcom Bio Chemicals Ind Ltd | Poultry feed and the use thereof |
| US7449451B2 (en) | 2001-08-29 | 2008-11-11 | Premier Micronutrient Corporation | Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks |
| GB2379854B (en) | 2001-09-19 | 2006-04-19 | Walcom Animal Science | Dairy cow feed and the use thereof |
| CN1596111A (zh) | 2001-11-29 | 2005-03-16 | 桑得医药品公司 | 减轻化疗引起的不良效果的组合物及方法 |
| KR20040078663A (ko) | 2002-01-04 | 2004-09-10 | 사운드 파마슈티칼스 인코퍼레이티드 | 난청의 치료 방법 |
| GB2386817B (en) | 2002-02-20 | 2006-08-23 | Walcom Animal Science | Feed for fish and use therof |
| US8017651B2 (en) | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
| GB2398497A (en) | 2003-02-19 | 2004-08-25 | Walcom Animal Science | Composition for improving immunity of animals |
| US8029822B2 (en) | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
| TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| WO2005049002A1 (en) | 2003-11-19 | 2005-06-02 | Omega Bio-Pharma International Ltd. | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
| RU2367423C2 (ru) | 2003-12-19 | 2009-09-20 | ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД | Композиции и способы для лечения диабета |
| US20050209441A1 (en) | 2004-03-22 | 2005-09-22 | Lile Jackson D | Process for promoting proper folding of human serum albumin using a human serum albumin ligand |
| CN1976691B (zh) | 2004-05-03 | 2010-10-13 | 奥加生物药业(I.P.3)有限公司 | 半胱胺用于治疗高胆固醇血症和糖尿病并发症 |
| KR20070119658A (ko) * | 2005-03-29 | 2007-12-20 | 에보니크 룀 게엠베하 | 활성 성분 방출에 대한 조절 효과를 가지는 물질을포함하는 펠렛을 포함하는 다중 미립자 제약 형태 |
| CA2605631A1 (en) | 2005-04-20 | 2006-10-26 | Fred Hutchinson Cancer Research Center | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms |
| AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| US20070172514A1 (en) | 2006-01-20 | 2007-07-26 | Francis Chi | Materials and methods for improving livestock productivity |
| ES2388310T7 (es) * | 2006-01-27 | 2017-05-03 | The Regents Of The University Of California | Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas |
| WO2009070781A1 (en) * | 2007-11-30 | 2009-06-04 | The Regents Of The University Of California | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products |
| CN102006785A (zh) | 2008-02-17 | 2011-04-06 | 华扩达动物科学(I.P.3)有限公司 | 改善虾健康的材料和方法 |
| EP2405898A2 (en) | 2009-03-09 | 2012-01-18 | Council Of Scientific & Industrial Research | Sustained release composition of therapeutic agent |
| JP5619130B2 (ja) * | 2009-03-18 | 2014-11-05 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ ＲｏｅｈｍＧｍｂＨ | 中性ビニルポリマーおよび賦形剤を含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物 |
| CN101653426A (zh) | 2009-09-16 | 2010-02-24 | 冯利萍 | 一种高稳型半胱胺盐酸盐的缓释小丸及制备方法 |
| CN101703472B (zh) * | 2009-11-09 | 2011-06-22 | 上海邦成生物科技有限公司 | 一种半胱胺盐酸盐制粒包衣缓释产品及其制备方法 |
| CN102077905B (zh) | 2010-12-10 | 2013-01-02 | 无锡正大畜禽有限公司 | 一种肠溶盐酸半胱胺包膜颗粒的生产方法 |
| WO2012170676A1 (en) * | 2011-06-08 | 2012-12-13 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| JP6411215B2 (ja) * | 2011-11-22 | 2018-10-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 虚血傷害を治療するためのシステアミンおよび／またはシスタミン |
| AR096628A1 (es) | 2013-06-17 | 2016-01-20 | Raptor Pharmaceuticals Inc | Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella |
-
2014
- 2014-06-16 AR ARP140102285A patent/AR096628A1/es not_active Application Discontinuation
- 2014-06-16 TW TW103120757A patent/TWI649100B/zh active
- 2014-06-17 CN CN201480034647.4A patent/CN105492000B/zh active Active
- 2014-06-17 EP EP14813132.9A patent/EP3010491A4/en active Pending
- 2014-06-17 CN CN201910990909.9A patent/CN110664780B/zh active Active
- 2014-06-17 AU AU2014281702A patent/AU2014281702C1/en active Active
- 2014-06-17 AP AP2015008925A patent/AP2015008925A0/xx unknown
- 2014-06-17 UA UAA201600331A patent/UA117833C2/uk unknown
- 2014-06-17 KR KR1020167000255A patent/KR102281747B1/ko active Active
- 2014-06-17 HK HK16105019.8A patent/HK1218066A1/zh unknown
- 2014-06-17 US US14/306,303 patent/US9233077B2/en active Active
- 2014-06-17 SG SG11201510126QA patent/SG11201510126QA/en unknown
- 2014-06-17 WO PCT/US2014/042607 patent/WO2014204881A1/en not_active Ceased
- 2014-06-17 KR KR1020217022957A patent/KR102466253B1/ko active Active
- 2014-06-17 JP JP2016521489A patent/JP6468661B2/ja active Active
- 2014-06-17 EA EA201690036A patent/EA031255B8/ru unknown
- 2014-06-17 BR BR112015031417-1A patent/BR112015031417B1/pt active IP Right Grant
- 2014-06-17 PH PH1/2020/552266A patent/PH12020552266A1/en unknown
- 2014-06-17 MX MX2015017366A patent/MX375377B/es active IP Right Grant
- 2014-06-17 EP EP21175359.5A patent/EP3939574A1/en active Pending
- 2014-06-17 TN TN2015000549A patent/TN2015000549A1/en unknown
- 2014-06-17 IL IL302141A patent/IL302141A/en unknown
- 2014-06-17 CA CA2938644A patent/CA2938644C/en active Active
- 2014-06-17 NZ NZ714517A patent/NZ714517A/en unknown
- 2014-06-17 CA CA2914770A patent/CA2914770C/en active Active
-
2015
- 2015-06-26 US US14/751,639 patent/US9173851B1/en active Active
- 2015-12-01 ZA ZA2015/08783A patent/ZA201508783B/en unknown
- 2015-12-11 US US14/966,490 patent/US20160095827A1/en not_active Abandoned
- 2015-12-14 PH PH12015502783A patent/PH12015502783A1/en unknown
- 2015-12-16 NI NI201500177A patent/NI201500177A/es unknown
- 2015-12-16 CU CUP2015000178A patent/CU20150178A7/es unknown
- 2015-12-17 CL CL2015003662A patent/CL2015003662A1/es unknown
-
2016
- 2016-02-12 US US15/042,823 patent/US20160158170A1/en not_active Abandoned
- 2016-07-26 US US15/220,308 patent/US20160331704A1/en not_active Abandoned
-
2017
- 2017-07-21 US US15/656,570 patent/US20170319513A1/en not_active Abandoned
- 2017-07-21 US US15/656,531 patent/US20170319512A1/en not_active Abandoned
- 2017-07-21 US US15/656,579 patent/US20170319514A1/en not_active Abandoned
-
2018
- 2018-12-12 US US16/218,136 patent/US11090279B2/en active Active
-
2021
- 2021-07-13 IL IL284823A patent/IL284823A/en unknown
-
2023
- 2023-03-16 AR ARP230100660A patent/AR128816A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523250A5 (enExample) | ||
| ES2486245T3 (es) | Sobre de mesalazina con alta carga de fármaco | |
| JP5220746B2 (ja) | 制御放出システム及びその製造方法 | |
| ES2823000T3 (es) | Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas | |
| JP6356215B2 (ja) | エベロリムスを含む医薬組成物 | |
| EA031255B1 (ru) | Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения | |
| ES2623176T3 (es) | Composición farmacéutica de memantina | |
| DK2265261T3 (en) | Medicinindgivelsessystemer comprising weakly basic drugs and organic acids | |
| JP2015205922A5 (enExample) | ||
| CA2905011C (en) | Extended-release topiramate capsules | |
| CN1134108A (zh) | 用于控释的新颗粒及含有该颗粒的药物制剂 | |
| EP3154523A1 (en) | Formulation for oral administration containing mesalazine | |
| MXPA06003602A (es) | Formulaciones de microparticulas de pantoprazol. | |
| JP2016517867A (ja) | タンパク質性サブコートを有する腸溶性の多微粒子組成物 | |
| JP2013512919A5 (enExample) | ||
| JP6510093B2 (ja) | ビロキサジンの緩和放出製剤 | |
| WO2012001705A2 (en) | Pharmaceutical compositions of (r)-lansoprazole | |
| CN103068374A (zh) | 代谢型谷氨酸受体5(mglu5)拮抗剂的药物组合物 | |
| CN103068372A (zh) | 代谢型谷氨酸受体5(mglu5)拮抗剂的药物组合物 | |
| US9555005B2 (en) | Extended-release topiramate capsules | |
| JP2015506980A5 (enExample) | ||
| JP2016516031A5 (enExample) | ||
| CN103520136B (zh) | 孟鲁斯特钠脉冲胶囊及其制备方法 | |
| WO2008079102A1 (en) | Modified release loxoprofen compositions | |
| Sudke | Design of modified release multiunit drug delivery system for the effective treatment of gastroesophageal diseases using hot-melt coating |